Further Information
ACTA2, ACTSA, actin, alpha 2, smooth muscle, aorta, alpha-cardiac actin, ACTVS, GIG46
Western blot: 1-2 ug/ml
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE): 0.25-0.5 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
The optimal dilution of the Smooth Muscle Actin antibody for each application should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Actin is a major component of the cytoskeleton and is present in most cell types. This mAb is highly specific to actin from smooth muscles. Its epitope lies in the first four N-terminal amino acids. This mAb does not stain cardiac or skeletal muscle; however, it does stain myofibroblasts and myoepithelial cells. This antibody could be used together with anti-muscle specific actin and myogenin in making a diagnosis of smooth muscle and skeletal muscle tumors. In most cases of rhabdomyosarcoma, this antibody yields negative results whereas anti-muscle specific actin and myogenin are positive. Leiomyosarcomas are positive only with anti-muscle specific actin and anti-smooth muscle actin and are negative with anti-myogenin.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
A 10 amino acid peptide from the alpha smooth muscle isoform of actin was used as the immunogen for this Smooth Muscle Actin antibody.
59
actin, alpha 2, smooth muscle, aorta
ACTA2
Homo sapiens
Liquid
Protein G affinity chromatography
Cancer
P62736
Optimal dilutions for each application to be determined by the researcher